Literature DB >> 27316276

Canadian preference and trends survey results for anti-VEGF treatment of macular edema.

Jaspreet S Rayat1, Parampal S Grewal1, James Whelan2, Matthew T S Tennant1, Netan Choudhry3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27316276     DOI： 10.1016/j.jcjo.2015.10.014

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN： 0008-4182            Impact factor:   1.882


× No keyword cloud information.
  3 in total

1.  Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up.

Authors:  Simon Javidi; Ali Dirani; Fares Antaki; Marc Saab; Sofiane Rahali; Ghassan Cordahi
Journal:  J Ophthalmol       Date:  2020-07-31       Impact factor: 1.909

2.  One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.

Authors:  Ali Salimi; Natalia Vila; Milad Modabber; Michael Kapusta
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

3.  Restructuring Wet Age-Related Macular Degeneration Services During the COVID-19 Pandemic to Allow Social Distancing Outpatient Clinics (SDOC).

Authors:  Markus Groppe; Mandeep Singh Bindra
Journal:  Clin Ophthalmol       Date:  2021-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.